FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andreas Hochhaus

Research Profile

Disorders

Chemicals & Drugs

Physiology

Concepts & Ideas

Procedures

Genes & Molecular Sequences

Genes, abl

Co-author Network

Publications

TOP 3
Steffen Heublein; Andreas Hochhaus; Britta Höchsmann; Michael Hartmann; Franziska Wehner; Paul La Rosée
Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany.
Andreas Hochhaus; Albert Hoenekopp; Carmino De Souza; Gabriel Etienne; Xiaolin Fan; Matt E Kalaycio; Hagop M Kantarjian; Dong-Wook Kim; Mineo Kurokawa; Richard A Larson; Gianantonio Rosti; Giuseppe Saglio; Yaping Shou; Timothy P Hughes
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Jorge Cortes; A R Craig; Raghunadharao Digumarti; Andreas Hochhaus; Hagop M Kantarjian; J H Lipton; F E Nicolini; P M Parikh; Meir Wetzler; A-C Benichou
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andreas Hochhaus (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Steffen Heublein; Andreas Hochhaus; Britta Höchsmann; Michael Hartmann; Franziska Wehner; Paul La Rosée
Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany.
Annals of hematology 2013;92(6):825-30.
2013: Andreas Hochhaus; Albert Hoenekopp; Carmino De Souza; Gabriel Etienne; Xiaolin Fan; Matt E Kalaycio; Hagop M Kantarjian; Dong-Wook Kim; Mineo Kurokawa; Richard A Larson; Gianantonio Rosti; Giuseppe Saglio; Yaping Shou; Timothy P Hughes
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood 2013;121(18):3703-8.
2013: Jorge Cortes; A R Craig; Raghunadharao Digumarti; Andreas Hochhaus; Hagop M Kantarjian; J H Lipton; F E Nicolini; P M Parikh; Meir Wetzler; A-C Benichou
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
American journal of hematology 2013;88(5):350-4.
2013: Ulf Schnetzke; Bärbel Spies-Weisshart; Elisabeth Zirm; Mike Fischer; Andreas Hochhaus; Anne-Kathrin Kuhn; Jörg P Müller; Sebastian Scholl
The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells.
Journal of cancer research and clinical oncology 2013;139(4):605-15.
2013: Andreas Hochhaus; Paul La Rosée
[Tailored management of chronic myeloid leukemia].
Der Internist 2013;54(2):155-6, 158-60, 162-3.
2012: Juliana Schwaab; Philipp Ströbel; Jenny Rinke; Susanne Schnittger; Nicholas C P Cross; Philipp Erben; Thomas Ernst; Torsten Haferlach; Andreas Hochhaus; Wolf-Karsten Hofmann; Georgia Metzgeroth; Max Mossner; Andreas Reiter
Activating CBL mutations are associated with a distinct MDS/MPN phenotype.
Annals of hematology 2012;91(11):1713-20.
2012: T Ernst; J F Beck; U Bierbach; J Ernst; Andreas Hochhaus; A Pflug; J Rinke; Bernd Gruhn
A somatic EZH2 mutation in childhood acute myeloid leukemia.
Leukemia 2012;26(7):1701-3.
2012: T Klag; Philipp Erben; N Härtel; Andreas Hochhaus; T Schenk; U Schnetzke; J Schwaab; Paul La Rosée
Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.
Leukemia 2012;26(6):1321-8.
2012: P D le Coutre; G J Ossenkoppele; Y Shou; Jane F Apperley; Michele Baccarani; R Blakesley; J Cortes; N J Gallagher; F J Giles; Andreas Hochhaus; H M Kantarjian
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
Leukemia 2012;26(6):1189-94.
2012: Elisabeth Zirm; Bärbel Spies-Weisshart; Frank-Dietmar Böhmer; Thomas Fischer; Florian Heidel; Andreas Hochhaus; Ulf Schnetzke; Sebastian Scholl
Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
British journal of haematology 2012;157(4):483-92.
2012: Hagop M Kantarjian; Dong-Wook Kim; Jorge H Milone; Franck E Nicolini; Michinori Ogura; Carolina Pavlovsky; Tadeusz Robak; Neil P Shah; María Soledad Undurraga; Jan Van Droogenbroeck; Edo Vellenga; Jianxiang Wang; Chao Zhu; Juan Julio Kassack Ipiña; Mohan B Agarwal; Michele Baccarani; M Brigid Bradley-Garelik; Jorge E Cortes; Christian Junghanss; Andreas Hochhaus
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Blood 2012;119(5):1123-9.
2012: Thomas Ernst; Andreas Hochhaus
Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression.
Seminars in oncology 2012;39(1):58-66.
2012: Nicolai Härtel; Andreas Hochhaus; Thomas Klag; Philipp Erben; Benjamin Hanfstein; Martin C Mueller; Thomas Schenk; Paul La Rosée
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Journal of cancer research and clinical oncology 2012;138(2):203-12.
2012: Ashu Kumari; Andreas Neubauer; Cornelia Brendel; Andreas Hochhaus; Andreas Burchert
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib.
Blood 2012;119(2):530-9.
2012: Mary Fuchs; Andreas Hochhaus; A Ragoschke-Schumm; Mike Reinhöfer; Herbert G Sayer; Otto W Witte; Klas Böer; Hubertus Axer
Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
BMC blood disorders 2012;12():9.
2012: Andreas Hochhaus; Thomas Ernst; Andreas Reiter; Paul La Rosée
Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disorders.
Onkologie 2012;35 Suppl 1():34-41.
2011: Philipp Erben; Benjamin Hanfstein; Andreas Hochhaus; Karoline Horisberger; Georg Kähler; Peter Kienle; Juliana Popa; Stefan Post; Philipp Ströbel; Frederik Wenz; Beatrice Bohn; Ralf-Dieter Hofheinz
KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
International journal of radiation oncology, biology, physics 2011;81(4):1032-8.
2011: Ulf Schnetzke; Sebastian Scholl; Theo Bossert; Martin Freesmeyer; Andreas Hochhaus; Paul La Rosée
Drug-induced lymphadenopathy with eosinophilia and renal failure mimicking lymphoma disease: dramatic onset of DRESS syndrome associated with antibiotic treatment.
Annals of hematology 2011;90(11):1353-5.
2011: Thomas Ernst; Paul La Rosée; Martin C Müller; Andreas Hochhaus
BCR-ABL mutations in chronic myeloid leukemia.
Hematology/oncology clinics of North America 2011;25(5):997-1008, v-vi.
2011: Maraike Rommeley; Herbert G Sayer; Kristina Schilling; Andreas Hochhaus; Baerbel Spies-Weisshart; Sebastian Scholl
Reconstitution and functional analyses of neutrophils and distinct subsets of monocytes after allogeneic stem cell transplantation.
Journal of cancer research and clinical oncology 2011;137(9):1293-300.
2011: Markus Pfirrmann; Susanne Saussele; Rüdiger Hehlmann; Andreas Hochhaus; M Lauseker; Joerg Hasford
Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.
Leukemia 2011;25(9):1433-8.
2011: Christoph Walz; Michael Ritter; Joannah Score; Nick Telford; Adrian Bloor; Nicholas C P Cross; Philipp Erben; Stefan Gesk; Claudia Haferlach; Torsten Haferlach; Andreas Hochhaus; Wolf-Karsten Hofmann; Georgia Metzgeroth; Andreas Reiter
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
Blood 2011;118(8):2239-42.
2011: Jorge E Cortes; Andreas Hochhaus; Philipp D le Coutre; Gianantonio Rosti; Javier Pinilla-Ibarz; Elias Jabbour; Kathryn Gillis; Richard C Woodman; Rick E Blakesley; Francis J Giles; Hagop M Kantarjian; Michele Baccarani
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
Blood 2011;117(21):5600-6.
2011: Rüdiger Hehlmann; Andreas Hochhaus; Dieter K Hossfeld; Susanne Jung-Munkwitz; Stefan W Krause; Michael Lauseker; Armin Leitner; Martin C Müller; Christoph Nerl; Markus Pfirrmann; Nadine Pletsch; Hans Pralle; Ulrike Proetel; Leopold Balleisen; Alois Gratwohl; Claudia Haferlach; Mathias Hänel; Joerg Hasford; Brigitte Schlegelberger; Susanne Saussele
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(12):1634-42.
2011: Sebastian Scholl; Baerbel Spies-Weisshart; Anne Klink; Lars-Olof Muegge; Hans-Joerg Fricke; Andreas Hochhaus
Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
Annals of hematology 2011;90(4):473-5.
2011: Nils Winkelmann; Iver Petersen; Michael Kiehntopf; Hans Joerg Fricke; Andreas Hochhaus; Ulrich Wedding
Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma.
Journal of cancer research and clinical oncology 2011;137(4):733-8.
2011: Benjamin Hanfstein; Martin C Müller; Sebastian Kreil; Thomas Ernst; Thomas Schenk; Christian Lorentz; Uwe Schwindel; Armin Leitner; Rüdiger Hehlmann; Andreas Hochhaus
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
Haematologica 2011;96(3):360-6.
2011: Jorge Cortes; Andreas Hochhaus; Timothy Hughes; Hagop Kantarjian
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):524-31.
2011: Hagop M Kantarjian; Francis J Giles; Kapil N Bhalla; Javier Pinilla-Ibarz; Richard A Larson; Norbert Gattermann; Oliver G Ottmann; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Timothy P Hughes; Giovanni Martinelli; Dong-Wook Kim; Yaping Shou; Neil J Gallagher; Rick Blakesley; Michele Baccarani; Jorge Cortes; Philipp D le Coutre
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
Blood 2011;117(4):1141-5.
2011: Armin A Leitner; Andreas Hochhaus; Martin C Müller
Current treatment concepts of CML.
Current cancer drug targets 2011;11(1):31-43.
2010: Jens Kruth; Johanna Nissen; Thomas Ernst; Melanie Kripp; Nadine Lukan; Kirsten Merx; Wolf-Karsten Hofmann; Andreas Hochhaus; Ralf-Dieter Hofheinz
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Journal of cancer research and clinical oncology 2010;136(12):1845-51.
2010: Thomas Ernst; Andrew Chase; Katerina Zoi; Katherine Waghorn; Claire Hidalgo-Curtis; Joannah Score; Amy Jones; Francis H Grand; Andreas Reiter; Andreas Hochhaus; Nicholas C P Cross
Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms.
Haematologica 2010;95(9):1473-80.
2010: Thomas Ernst; Andrew Chase; Joannah Score; Claire E Hidalgo-Curtis; Catherine Bryant; Amy V Jones; Katherine Waghorn; Katerina Zoi; Fiona M Ross; Andreas Reiter; Andreas Hochhaus; Hans G Drexler; Andrew Duncombe; Francisco Cervantes; David Oscier; Jacqueline Boultwood; Francis H Grand; Nicholas C P Cross
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.
Nature genetics 2010;42(8):722-6.
2010: Michelle Giehl; Armin Leitner; Claudia Haferlach; Peter Duesberg; Wolf-Karsten Hofmann; Ralf Hofheinz; Wolfgang Seifarth; Andreas Hochhaus; Alice Fabarius
Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors.
European journal of haematology 2010;85(2):139-48.
2010: Andrew Lamb; Neil P Shah; Andreas Hochhaus; Jorge Cortes; Sandip Shah; Manuel Ayala; Beatriz Moiraghi; Zhixiang Shen; Jiri Mayer; Ricardo Pasquini; Hirohisa Nakamae; Françoise Huguet; Concepción Boqué; Charles Chuah; Eric Bleickardt; M Brigid Bradley-Garelik; Chao Zhu; Ted Szatrowski; David Shapiro; Michele Baccarani
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
The New England journal of medicine 2010;362(24):2260-70.
2010: Andrew Lamb; Phillipp le Coutre; Jorge Cortes; Javier Pinilla-Ibarz; Arnon Nagler; Andreas Hochhaus; Shinya Kimura; Oliver G Ottmann
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
Cancer 2010;116(11):2665-72.
2010: Christoph Walz; David Grimwade; Susanne Saussele; Eva Lengfelder; Claudia Haferlach; Susanne Schnittger; Marina Lafage-Pochitaloff; Andreas Hochhaus; Nicholas C P Cross; Andreas Reiter
Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemia.
Genes, chromosomes & cancer 2010;49(5):471-9.
2010: Philipp Erben; Darko Gosenca; Martin C Müller; Jelena Reinhard; Joannah Score; Francesco Del Valle; Christoph Walz; Jürgen Mix; Georgia Metzgeroth; Thomas Ernst; Claudia Haferlach; Nicholas C P Cross; Andreas Hochhaus; Andreas Reiter
Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.
Haematologica 2010;95(5):738-44.
2010: Hagop M Kantarjian; Jorge Cortes; Paul La Rosée; Andreas Hochhaus
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Cancer 2010;116(6):1419-30.
2010: Susanne Saussele; Michael Lauseker; Alois Gratwohl; Dietrich W Beelen; Donald Bunjes; Rainer Schwerdtfeger; Hans-Jochem Kolb; Anthony D Ho; Christiane Falge; Ernst Holler; Günter Schlimok; Axel R Zander; Renate Arnold; Lothar Kanz; Robert Dengler; Claudia Haferlach; Brigitte Schlegelberger; Markus Pfirrmann; Martin C Müller; Susanne Schnittger; Armin Leitner; Nadine Pletsch; Andreas Hochhaus; Joerg Hasford; Rüdiger Hehlmann
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Blood 2010;115(10):1880-5.
2010: Karoline Horisberger; Philipp Erben; Philipp Ströbel; Beatrice Bohn; Melanie Hahn; Georg Kähler; Frederik Wenz; Andreas Hochhaus; Stefan Post; Frank Willeke; Ralf-Dieter Hofheinz
Annexin and survivin in locally advanced rectal cancer: indicators of resistance to preoperative chemoradiotherapy?
Onkologie 2010;33(8-9):439-44.
2010: Sebastian Kreil; Katherine Waghorn; Thomas Ernst; Andrew Chase; Helen White; Rüdiger Hehlmann; Andreas Reiter; Andreas Hochhaus; Nicholas C P Cross
A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon α.
Haematologica 2010;95(1):148-52.
2010: Elias Jabbour; Andreas Hochhaus; Jorge Cortes; P La Rosée; Hagop M Kantarjian
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Leukemia 2010;24(1):6-12.
2009: Timothy Hughes; Giuseppe Saglio; Susan Branford; Simona Soverini; Dong-Wook Kim; Martin C Müller; Giovanni Martinelli; Jorge Cortes; Lan Beppu; Enrico Gottardi; Dongho Kim; Philipp Erben; Yaping Shou; Ariful Haque; Neil Gallagher; Jerald Radich; Andreas Hochhaus
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(25):4204-10.
2009: Karoline Horisberger; Anne Treschl; Sabine Mai; Manuel Barreto-Miranda; Peter Kienle; Philipp Ströbel; Philipp Erben; Christoph Woernle; Dietmar Dinter; Georg Kähler; Andreas Hochhaus; Stefan Post; Frank Willeke; Frederik Wenz; Ralf-Dieter Hofheinz
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
International journal of radiation oncology, biology, physics 2009;74(5):1487-93.
2009: Jane F Apperley; Jorge E Cortes; Dong-Wook Kim; Lydia Roy; Gail J Roboz; Gianantonio Rosti; Eduardo O Bullorsky; Elisabetta Abruzzese; Andreas Hochhaus; Dominik Heim; Carmino A de Souza; Richard A Larson; Jeffrey H Lipton; H Jean Khoury; Hyeoung-Joon Kim; Christian Sillaber; Timothy P Hughes; Philipp Erben; Jan M. Van Tornout; Richard M Stone
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3472-9.
2009: Karoline Horisberger; Philipp Erben; Benjamin Muessle; Christoph Woernle; Philipp Stroebel; Georg Kaehler; Frederik Wenz; Andreas Hochhaus; Stefan Post; Frank Willeke; Ralf-Dieter Hofheinz
Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer.
Anti-cancer drugs 2009;20(6):519-24.
2009: Timothy Hughes; Andreas Hochhaus
Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy.
Seminars in hematology 2009;46(2 Suppl 3):S11-5.
2009: Christoph Walz; J Score; J Mix; D Cilloni; C Roche-Lestienne; R-F Yeh; J L Wiemels; E Ottaviani; Philipp Erben; Andreas Hochhaus; M Baccarani; D Grimwade; Claude Preudhomme; J Apperley; giovanni martinelli; Giuseppe Saglio; Nicholas C P Cross; Andreas Reiter
The molecular anatomy of the FIP1L1-PDGFRA fusion gene.
Leukemia 2009;23(2):271-8.
2008: Philipp Erben; Karoline Horisberger; Benjamin Muessle; Martin Christian Müller; Anne Treschl; Thomas Ernst; Georg Kähler; Philipp Ströbel; Frederik Wenz; Peter Kienle; Stefan Post; Andreas Hochhaus; Frank Willeke; Ralf-Dieter Hofheinz
mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer.
International journal of radiation oncology, biology, physics 2008;72(5):1544-50.
2008: Georgia Metzgeroth; Christoph Walz; Philipp Erben; Helena Popp; Annette Schmitt-Graeff; Claudia Haferlach; Alice Fabarius; Susanne Schnittger; David Grimwade; Nicholas C P Cross; Rüdiger Hehlmann; Andreas Hochhaus; Andreas Reiter
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
British journal of haematology 2008;143(5):707-15.
2008: Susan Branford; Linda Fletcher; Nicholas C P Cross; Martin C Müller; Andreas Hochhaus; Dong-Wook Kim; Jerald P Radich; Giuseppe Saglio; Fabrizio Pane; Suzanne Kamel-Reid; Y Lynn Wang; Richard D Press; Kevin Lynch; Zbigniew Rudzki; John M Goldman; Timothy Hughes
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.
Blood 2008;112(8):3330-8.
2008: Thomas Ernst; Jana Hoffmann; Philipp Erben; Benjamin Hanfstein; Armin Leitner; Rüdiger Hehlmann; Andreas Hochhaus; Martin C Müller
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Haematologica 2008;93(9):1389-93.
2008: Alice Fabarius; Michelle Giehl; Blanka Rebacz; Alwin Krämer; Oliver Frank; Claudia Haferlach; Peter Duesberg; Rüdiger Hehlmann; Wolfgang Seifarth; Andreas Hochhaus
Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib.
Haematologica 2008;93(8):1145-54.
2008: Paul La Rosée; Susanne Holm-Eriksen; Heiko Konig; Nicolai Härtel; Thomas Ernst; Julia Debatin; Martin C Mueller; Philipp Erben; Anja Binckebanck; Lydia Wunderle; Yaping Shou; Margaret Dugan; Rüdiger Hehlmann; Oliver G Ottmann; Andreas Hochhaus
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
Haematologica 2008;93(5):765-9.
2008: Paul La Rosée; Andreas Hochhaus
Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.
Current hematologic malignancy reports 2008;3(2):72-9.
2008: Andreas Hochhaus
First-Line management of CML: a state of the art review.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6 Suppl 2():S1-S10.
2008: Karoline Horisberger; Ralf-Dieter Hofheinz; Pablo Palma; A K Volkert; S Rothenhoefer; Frederik Wenz; Andreas Hochhaus; Stefan Post; Frank Willeke
Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity?
International journal of colorectal disease 2008;23(3):257-64.
2008: Philipp le Coutre; Oliver G Ottmann; Francis Giles; Dong-Wook Kim; Jorge Cortes; Norbert Gattermann; Jane F Apperley; Richard A Larson; Elisabetta Abruzzese; Stephen G O'Brien; Kazimierz Kuliczkowski; Andreas Hochhaus; Francois-Xavier Mahon; Giuseppe Saglio; marco gobbi; Yok-Lam Kwong; Michele Baccarani; Timothy Hughes; giovanni martinelli; Jerald P Radich; Ming Zheng; Yaping Shou; Andrew Lamb
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
Blood 2008;111(4):1834-9.
2008: Thomas Ernst; Philipp Erben; Martin C Müller; Peter Paschka; Thomas Schenk; Jana Hoffmann; Sebastian Kreil; Paul La Rosée; Rüdiger Hehlmann; Andreas Hochhaus
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Haematologica 2008;93(2):186-92.
2008: Alice Fabarius; Peter Duesberg; Michelle Giehl; Wolfgang Seifarth; Andreas Hochhaus; Rüdiger Hehlmann
Genomic instability in context of the chromosomal theory.
Cellular oncology : the official journal of the International Society for Cellular Oncology 2008;30(6):503-4.
2008: Thomas Ernst; Jana Hoffmann; Philipp Erben; Rüdiger Hehlmann; Andreas Hochhaus; Martin C Müller
Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(3):318-22.
2008: Martin C Müller; Philipp Erben; Giuseppe Saglio; Enrico Gottardi; C G Nyvold; T Schenk; T Ernst; S Lauber; J Kruth; Rüdiger Hehlmann; Andreas Hochhaus
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories.
Leukemia 2008;22(1):96-102.
2007: Hagop M Kantarjian; Francis Giles; Norbert Gattermann; Kapil N Bhalla; Giuliana Alimena; Francesca Palandri; Gert Ossenkoppele; Franck-Emmanuel Nicolini; Stephen G O'Brien; Mark R Litzow; Ravi Bhatia; Francisco Cervantes; Ariful Haque; Yaping Shou; Debra Resta; Aaron Weitzman; Andreas Hochhaus; Philipp le Coutre
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Blood 2007;110(10):3540-6.
2007: Michael W N Deininger; Jorge Cortes; Ron Paquette; Byung S Park; Andreas Hochhaus; Michele Baccarani; Richard M Stone; Thomas Fischer; Andrew Lamb; Dietger Niederwieser; Carlo Gambacorti-Passerini; Charlene So; Insa Gathmann; John M Goldman; B Douglas Smith; Brian J Druker; françois guilhot
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Cancer 2007;110(7):1509-19.
2007: Oliver G Ottmann; Hervé Dombret; giovanni martinelli; Bengt Simonsson; françois guilhot; Richard A Larson; Giovanna Rege-Cambrin; Jerald P Radich; Andreas Hochhaus; Anne Marie Apanovitch; Ashwin Gollerkeri; Steven Coutre
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
Blood 2007;110(7):2309-15.
2007: Michelle Giehl; Alice Fabarius; Oliver Frank; Philipp Erben; Chun Zheng; M Hafner; Andreas Hochhaus; Rüdiger Hehlmann; Wolfgang Seifarth
Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells.
Leukemia 2007;21(9):1971-6.
2007: Sebastian Kreil; Markus Pfirrmann; Claudia Haferlach; Katherine Waghorn; Andrew Chase; Rüdiger Hehlmann; Andreas Reiter; Andreas Hochhaus; Nicholas C P Cross
Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia.
Blood 2007;110(4):1283-90.
2007: Alice Fabarius; Michelle Giehl; Oliver Frank; Birgit Spiess; Chun Zheng; Martin C Müller; Christel Weiss; Peter Duesberg; Rüdiger Hehlmann; Andreas Hochhaus; Wolfgang Seifarth
Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability.
British journal of haematology 2007;138(3):369-73.
2007: Rüdiger Hehlmann; Andreas Hochhaus; Michele Baccarani
Chronic myeloid leukaemia.
Lancet 2007;370(9584):342-50.
2007: Heike Pfeifer; Barbara Wassmann; Anna Pavlova; Lydia Wunderle; Johannes Oldenburg; Anja Binckebanck; Thoralf Lange; Andreas Hochhaus; Silvia Wystub; Patrick Brück; Dieter Hoelzer; Oliver G Ottmann
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood 2007;110(2):727-34.
2007: Alwin Krämer; Andreas Reiter; Jens Kruth; Philipp Erben; Andreas Hochhaus; Martin Müller; Nicholas C P Cross; Amy V Jones; Anthony Ho; Manfred Hensel
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.
The lancet oncology 2007;8(7):658-60.
2007: Martin C Müller; Guiseppe Saglio; Feng Lin; Heike Pfeifer; Richard D Press; Raymond R Tubbs; Peter Paschka; Enrico Gottardi; Steven G O'Brien; Oliver G Ottmann; Hubertus Stockinger; Lothar Wieczorek; Kirsten Merx; Heiko König; Uwe Schwindel; Rüdiger Hehlmann; Andreas Hochhaus
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR.
Haematologica 2007;92(7):970-3.
2007: H Menzel; Nikolas von Bubnoff; Andreas Hochhaus; C Haferlach; Christian Peschel; Justus Duyster
Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib.
Bone marrow transplantation 2007;40(1):83-4.
2007: Jochen Utikal; Selma Ugurel; Hjalmar Kurzen; Philipp Erben; Andreas Reiter; Andreas Hochhaus; Thomas Nebe; Ralf Hildenbrand; Uwe Haberkorn; Sergij Goerdt; Dirk Schadendorf
Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses.
Archives of dermatology 2007;143(6):736-40.
2007: Heiko Konig; Nicolai Härtel; Beate Schultheis; Michael Schatz; Christian Lorentz; Junia V Melo; Rüdiger Hehlmann; Andreas Hochhaus; Paul La Rosée
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Haematologica 2007;92(6):838-41.
2007: Alice Fabarius; Claudia Haferlach; Martin C Müller; Philipp Erben; Tanja Lahaye; Michelle Giehl; Oliver Frank; Wolfgang Seifarth; Rüdiger Hehlmann; Andreas Hochhaus
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure.
Haematologica 2007;92(6):834-7.
2007: Georgia Metzgeroth; Christoph Walz; Joannah Score; R Siebert; S Schnittger; Claudia Haferlach; H Popp; Torsten Haferlach; Philipp Erben; J Mix; Martin C Müller; H Beneke; L Müller; F Del Valle; Walter Aulitzky; G Wittkowsky; Norbert Schmitz; C Schulte; K Müller-Hermelink; E Hodges; S J Whittaker; F Diecker; H Döhner; P Schuld; Rüdiger Hehlmann; Andreas Hochhaus; Nicholas C P Cross; Andreas Reiter
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Leukemia 2007;21(6):1183-8.
2007: Rüdiger Hehlmann; Ute Berger; Markus Pfirrmann; Hermann Heimpel; Andreas Hochhaus; Joerg Hasford; Hans-Jochem Kolb; Tanja Lahaye; Ole Maywald; Andreas Reiter; Dieter K Hossfeld; Christoph Huber; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Andreas Tobler; Christoph Nerl; Max Solenthaler; Mariele E Goebeler; Martin Griesshammer; Thomas Fischer; Stephan Kremers; Hartmut Eimermacher; Michael Pfreundschuh; Wolf-Dietrich Hirschmann; Klaus Lechner; Barbara Wassmann; Christiane Falge; Hartmut H Kirchner; Alois Gratwohl
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.
Blood 2007;109(11):4686-92.
2007: Jelena V Jovanovic; Joannah Score; Katherine Waghorn; Daniela Cilloni; Enrico Gottardi; Georgia Metzgeroth; Philipp Erben; Helena Popp; Christoph Walz; Andreas Hochhaus; Catherine Roche-Lestienne; Claude Preudhomme; Ellen Solomon; Jane Apperley; Michela Rondoni; Emanuela Ottaviani; giovanni martinelli; Finella Brito-Babapulle; Giuseppe Saglio; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter; David Grimwade
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
Blood 2007;109(11):4635-40.
2007: françois guilhot; Jane Apperley; Dong-Wook Kim; Eduardo O Bullorsky; Michele Baccarani; Gail J Roboz; Sergio Amadori; Carmino Antonio De Souza; Jeffrey H Lipton; Andreas Hochhaus; Dominik Heim; Richard A Larson; Susan Branford; Martin C Muller; Prasheen Agarwal; Ashwin Gollerkeri; Moshe Talpaz
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Blood 2007;109(10):4143-50.
2007: Stefan Fruehauf; Julian Topaly; Eike C Buss; Thomas Fischer; Oliver G Ottmann; Bertold Emmerich; Martin C Müller; Peter Schuld; Leopold Balleisen; Rüdiger Hehlmann; Anthony Ho; Andreas Hochhaus
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Cancer 2007;109(8):1543-9.
2007: Jorge Cortes; Philippe Rousselot; Dong-Wook Kim; Ellen Ritchie; Nelson Hamerschlak; Steven Coutre; Andreas Hochhaus; françois guilhot; Giuseppe Saglio; Jane Apperley; Oliver G Ottmann; Neil Shah; Philipp Erben; Susan Branford; Prasheen Agarwal; Ashwin Gollerkeri; Michele Baccarani
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Blood 2007;109(8):3207-13.
2007: Hagop M Kantarjian; Jorge Cortes; françois guilhot; Andreas Hochhaus; Michele Baccarani; Lee Lokey
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
Cancer 2007;109(7):1365-75.
2007: Frank Willeke; Karoline Horisberger; Uta Kraus-Tiefenbacher; Frederik Wenz; A Leitner; Andreas Hochhaus; Rainer Grobholz; Andreas Willer; G Kähler; Stefan Post; Ralf-Dieter Hofheinz
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
British journal of cancer 2007;96(6):912-7.
2007: Andreas Hochhaus; Hagop M Kantarjian; Michele Baccarani; Jeffrey H Lipton; Jane F Apperley; Brian J Druker; Thierry Facon; Stuart L Goldberg; Francisco Cervantes; Dietger Niederwieser; Richard T Silver; Richard M Stone; Timothy P Hughes; Martin C Muller; Rana Ezzeddine; Athena M Countouriotis; Neil P Shah
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Blood 2007;109(6):2303-9.
2007: Ying Wang; Dali Cai; Cornelia Brendel; Christine Barett; Philipp Erben; Paul W Manley; Andreas Hochhaus; Andreas Neubauer; Andreas Burchert
Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation.
Blood 2007;109(5):2147-55.
2007: Christoph Walz; Georgia Metzgeroth; Claudia Haferlach; Annette Schmitt-Graeff; Alice Fabarius; Volker Hagen; Otto Prümmer; Stefan Rauh; Rüdiger Hehlmann; Andreas Hochhaus; Nicholas C P Cross; Andreas Reiter
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
Haematologica 2007;92(2):163-9.
2007: Andreas Hochhaus; Philipp Erben; Thomas Ernst; Martin C Mueller
Resistance to targeted therapy in chronic myelogenous leukemia.
Seminars in hematology 2007;44(1 Suppl 1):S15-24.
2006: Ralf-Dieter Hofheinz; Stefan Kubicka; Jörg Wollert; Dirk Arnold; Andreas Hochhaus
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Onkologie 2006;29(12):563-7.
2006: Ralf-Dieter Hofheinz; Karoline Horisberger; Christoph Woernle; Frederik Wenz; Uta Kraus-Tiefenbacher; Georg Kähler; Dietmar Dinter; Rainer Grobholz; Steffen Heeger; Stefan Post; Andreas Hochhaus; Frank Willeke
Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
International journal of radiation oncology, biology, physics 2006;66(5):1384-90.
2006: Susan Branford; Nicholas C P Cross; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Jaspal Kaeda; J Goldman; Timothy Hughes
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia.
Leukemia 2006;20(11):1925-30.
2006: Susanne Saussele; K Adam; Andreas Hochhaus; marie bene; Thomas Büchner; A Burnett; G Finazzi; Christa Fonatsch; E Gluckman; Nicola Gökbuget; David Grimwade; Torsten Haferlach; M Hallek; Joerg Hasford; Dieter Hoelzer; P Ljungman; Dietger Niederwieser; Hubert Serve; B Simonsson; T J de Witte; Rüdiger Hehlmann
[Clinical research at the European LeukemiaNet].
Deutsche medizinische Wochenschrift (1946) 2006;131(43):2423-6.
2006: Christoph Walz; Claire Curtis; Susanne Schnittger; Beate Schultheis; Georgia Metzgeroth; Claudia Schoch; Eva Lengfelder; Philipp Erben; Martin C Müller; Torsten Haferlach; Andreas Hochhaus; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
Genes, chromosomes & cancer 2006;45(10):950-6.
2006: Oliver Frank; B Brors; Alice Fabarius; L Li; Markus Haak; Sylvia Merk; Uwe Schwindel; Chun Zheng; Martin C Müller; Norbert Gretz; Rüdiger Hehlmann; Andreas Hochhaus; Wolfgang Seifarth
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients.
Leukemia 2006;20(8):1400-7.
2006: Timothy Hughes; Michael W N Deininger; Andreas Hochhaus; Susan Branford; Jerald P Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; giovanni martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Blood 2006;108(1):28-37.
2006: Andrew Lamb; Francis Giles; Lydia Wunderle; Kapil N Bhalla; Susan O'Brien; Barbara Wassmann; Chiaki Tanaka; Paul Manley; Patricia Rae; William Mietlowski; Kathy Bochinski; Andreas Hochhaus; James D Griffin; Dieter Hoelzer; Maher Albitar; Margaret Dugan; Jorge Cortes; Leila Alland; Oliver G Ottmann
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
The New England journal of medicine 2006;354(24):2542-51.
2006: Chun Zheng; L Li; Markus Haak; B Brors; Oliver Frank; Michelle Giehl; Alice Fabarius; M Schatz; Andreas Weisser; C Lorentz; Norbert Gretz; Rüdiger Hehlmann; Andreas Hochhaus; Wolfgang Seifarth
Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis.
Leukemia 2006;20(6):1028-34.
2006: Amy V Jones; Richard T Silver; Katherine Waghorn; Claire Curtis; Sebastian Kreil; Katerina Zoi; Andreas Hochhaus; David Oscier; Georgia Metzgeroth; Eva Lengfelder; Andreas Reiter; Andrew Chase; Nicholas C P Cross
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.
Blood 2006;107(8):3339-41.
2006: Ole Maywald; Markus Pfirrmann; Ute Berger; Lusine Breitscheidel; Alois Gratwohl; Hans-Jochem Kolb; D W Beelen; Andreas Tobler; Georgia Metzgeroth; S U Gnad; Andreas Hochhaus; Joerg Hasford; Rüdiger Hehlmann; Andreas Reiter
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia.
Leukemia 2006;20(3):477-84.
2005: Ralf-Dieter Hofheinz; Christian Dittrich; Michael A Jakupec; A Drescher; Ulrich Jaehde; Margit Gneist; Nikolai Graf von Keyserlingk; Bernhard K Keppler; Andreas Hochhaus
Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV).
International journal of clinical pharmacology and therapeutics 2005;43(12):590-1.
2005: Andreas Burchert; Ying Wang; Dali Cai; Nikolas von Bubnoff; P Paschka; Sabine Müller-Brüsselbach; O G Ottmann; Justus Duyster; Andreas Hochhaus; Andreas Neubauer
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Leukemia 2005;19(10):1774-82.
2005: Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
Blood 2005;106(6):2162-8.
2005: Alice Fabarius; Michelle Giehl; Oliver Frank; Peter Duesberg; Andreas Hochhaus; Rüdiger Hehlmann; Wolfgang Seifarth
Induction of centrosome and chromosome aberrations by imatinib in vitro.
Leukemia 2005;19(9):1573-8.
2005: Ralf-Dieter Hofheinz; Senta Ulrike Gnad-Vogt; Ulrich Beyer; Andreas Hochhaus
Liposomal encapsulated anti-cancer drugs.
Anti-cancer drugs 2005;16(7):691-707.
2005: Rüdiger Hehlmann; Ute Berger; Andreas Hochhaus
Chronic myeloid leukemia: a model for oncology.
Annals of hematology 2005;84(8):487-97.
2005: Michelle Giehl; Alice Fabarius; Oliver Frank; Andreas Hochhaus; M Hafner; Rüdiger Hehlmann; Wolfgang Seifarth
Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability.
Leukemia 2005;19(7):1192-7.
2005: Gernot Hartung; Ralf-Dieter Hofheinz; Y Dencausse; Jörg Sturm; Annette Kopp-Schneider; G Dietrich; I Fackler-Schwalbe; D Bornbusch; M Gonnermann; C Wojatschek; W Lindemann; H Eschenburg; K Jost; Lutz Edler; Andreas Hochhaus; Wolfgang Queisser
Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study.
Onkologie 2005;28(6-7):347-50.
2005: Ute Berger; Ole Maywald; Markus Pfirrmann; Tanja Lahaye; Andreas Hochhaus; Andreas Reiter; Joerg Hasford; Hermann Heimpel; Dieter K Hossfeld; Hans-Jochem Kolb; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Rüdiger Hehlmann
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
Leukemia 2005;19(6):984-9.
2005: Christoph Walz; Andrew Chase; Claudia Schoch; Andreas Weisser; F Schlegel; Andreas Hochhaus; R Fuchs; A Schmitt-Gräff; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter
The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1.
Leukemia 2005;19(6):1005-9.
2005: Selma Ugurel; Ralf Hildenbrand; Anette Zimpfer; Paul La Rosée; Peter Paschka; Antje Sucker; Petra Keikavoussi; Jürgen C Becker; Werner Rittgen; Andreas Hochhaus; Dirk Schadendorf
Lack of clinical efficacy of imatinib in metastatic melanoma.
British journal of cancer 2005;92(8):1398-405.
2005: Tanja Lahaye; Birte Riehm; Ute Berger; Peter Paschka; Martin C Müller; Sebastian Kreil; Kirsten Merx; Uwe Schwindel; Claudia Schoch; Rüdiger Hehlmann; Andreas Hochhaus
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Cancer 2005;103(8):1659-69.
2005: Joerg Hasford; Markus Pfirrmann; Andreas Hochhaus
How long will chronic myeloid leukemia patients treated with imatinib mesylate live?
Leukemia 2005;19(4):497-9.
2005: Lucy C Crossman; Motomi Mori; Yi-Ching Hsieh; Thoralf Lange; Peter Paschka; Christina A Harrington; Knut Krohn; Dietger Niederwieser; Rüdiger Hehlmann; Andreas Hochhaus; Brian J Druker; Michael W N Deininger
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.
Haematologica 2005;90(4):459-64.
2005: Andreas Reiter; Christoph Walz; Ann Watmore; Claudia Schoch; Ilona Blau; Brigitte Schlegelberger; Ute Berger; Nick Telford; Shilani Aruliah; John A Yin; Danny Vanstraelen; Helen F Barker; Peter C Taylor; Aisling O'Driscoll; Fabio Benedetti; Cornelia Rudolph; Hans-Jochem Kolb; Andreas Hochhaus; Rüdiger Hehlmann; Andrew Chase; Nicholas C P Cross
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
Cancer research 2005;65(7):2662-7.
2005: Senta Ulrike Gnad-Vogt; Ralf-Dieter Hofheinz; Susanne Saussele; Sebastian Kreil; Andreas Willer; Frank Willeke; Lothar Pilz; Rüdiger Hehlmann; Andreas Hochhaus
Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial.
Anti-cancer drugs 2005;16(4):435-40.
2005: Shadmehr Demehri; Peter Paschka; Beate Schultheis; Thoralf Lange; T Koizumi; T Sugimoto; S Branford; L C Lim; T Kegel; giovanni martinelli; Andreas Hochhaus; Brian J Druker; Michael W N Deininger
e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants?
Leukemia 2005;19(4):681-4.
2005: Ralf-Dieter Hofheinz; Bolko von Gerstenberg-Helldorf; Frederik Wenz; Ulrike Gnad; Uta Kraus-Tiefenbacher; Albrecht Müldner; Rüdiger Hehlmann; Stefan Post; Andreas Hochhaus; Frank Willeke
Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(7):1350-7.
2005: Dirk Neuhof; Florian Neumayer; Wolfgang Einbeck; Kai Haschemian; Sabine K Mai; Andreas Hochhaus; Frank Willeke; Jochen Rudi; Jürgen Debus; Frederik Wenz
Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer.
Acta oncologica (Stockholm, Sweden) 2005;44(2):168-73.
2005: Ralf-Dieter Hofheinz; Ulrike Gnad-Vogt; Axel Wein; Susanne Saussele; Sebastian Kreil; Lothar Pilz; Rüdiger Hehlmann; Andreas Hochhaus
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Anti-cancer drugs 2005;16(1):39-45.
2004: Andreas Hochhaus; Ute Berger; Rüdiger Hehlmann
[Therapy of chronic myelogenous leukemia in 2004].
Deutsche medizinische Wochenschrift (1946) 2004;129(40):2122-7.
2004: Ralf-Dieter Hofheinz; Jörg Thomas Hartmann; Andreas Willer; Karin Oechsle; Gernot Hartung; Ulrike Gnad; Susanne Saussele; Sebastian Kreil; Carsten Bokemeyer; Rüdiger Hehlmann; Andreas Hochhaus
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial.
British journal of cancer 2004;91(5):834-8.
2004: Stefan Faderl; Andreas Hochhaus; Timothy Hughes
Monitoring of minimal residual disease in chronic myeloid leukemia.
Hematology/oncology clinics of North America 2004;18(3):657-70, ix-x.
2004: Andreas Hochhaus; Timothy Hughes
Clinical resistance to imatinib: mechanisms and implications.
Hematology/oncology clinics of North America 2004;18(3):641-56, ix.
2004: Ralf-Dieter Hofheinz; Andreas Willer; Andreas Weisser; Ulrike Gnad; Susanne Saussele; Sebastian Kreil; Jörg Thomas Hartmann; Rüdiger Hehlmann; Andreas Hochhaus
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.
British journal of cancer 2004;90(10):1893-7.
2004: Andreas Burchert; Dali Cai; Lorenz C Hofbauer; Magnus K R Samuelsson; Emily P Slater; Justus Duyster; Markus Ritter; Andreas Hochhaus; Rolf Mueller; Martin Eilers; Manuel Schmidt; Andreas Neubauer
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.
Blood 2004;103(9):3480-9.
2004: Ute Berger; Georg Engelich; Andreas Reiter; Andreas Hochhaus; Rüdiger Hehlmann
Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia.
Annals of hematology 2004;83(4):258-64.
2004: Ralf-Dieter Hofheinz; Xuan Duc Nguyen; Dieter Buchheidt; Mohammed Kerowgan; Rüdiger Hehlmann; Andreas Hochhaus
Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient.
Cancer chemotherapy and pharmacology 2004;53(3):276-7.
2004: Peter Paschka; Kirsten Merx; Andreas Hochhaus
Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistance.
Acta haematologica 2004;112(1-2):85-92.
2004: Martin C Müller; Tanja Hördt; Peter Paschka; Kirsten Merx; Paul La Rosée; Rüdiger Hehlmann; Andreas Hochhaus
Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia.
Acta haematologica 2004;112(1-2):30-3.
2004: Andreas Hochhaus
Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Annals of hematology 2004;83 Suppl 1():S65-6.
2003: Andreas Hochhaus
A further milestone towards comprehensive standardization of quantitative RT-PCR protocols for leukemic fusion gene transcripts has been reached.
Leukemia 2003;17(12):2383-4.
2003: Martin C Müller; Norbert Gattermann; Tanja Lahaye; Michael W N Deininger; A Berndt; Stefan Fruehauf; Andreas Neubauer; Thomas Fischer; Dieter K Hossfeld; Folker Schneller; S W Krause; Christoph Nerl; Herbert G Sayer; Oliver G Ottmann; C Waller; Walter Aulitzky; Philipp le Coutre; Mathias Freund; Kirsten Merx; Peter Paschka; Heiko König; Sebastian Kreil; Ute Berger; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Leukemia 2003;17(12):2392-400.
2003: Tomasz Sacha; Andreas Hochhaus; Benjamin Hanfstein; Martin C Müller; Zbigniew Rudzki; Jacek Czopek; Teresa Wolska-Smoleń; Sylwia Czekalska; Zoriana Salamanchuk; Malgorzata Jakóbczyk; Aleksander B Skotnicki
ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis.
Leukemia research 2003;27(12):1163-6.
2003: Timothy P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
The New England journal of medicine 2003;349(15):1423-32.
2003: Ute Berger; Georg Engelich; Ole Maywald; Markus Pfirrmann; Andreas Hochhaus; Andreas Reiter; Georgia Metzgeroth; U Gnad; Joerg Hasford; Barbara Heinze; Hermann Heimpel; Dieter K Hossfeld; Hans-Jochem Kolb; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Rüdiger Hehlmann
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
Leukemia 2003;17(9):1820-6.
2003: Peter Paschka; Martin C Müller; Kirsten Merx; Sebastian Kreil; Claudia Schoch; Tanja Lahaye; Andreas Weisser; A Petzold; Heiko König; Ute Berger; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Leukemia 2003;17(9):1687-94.
2003: Tim H Brummendorf; Inci Ersoz; Ulrike Hartmann; Stefan Balabanov; Holger Wolke; Peter Paschka; Tanja Lahaye; Birgit Berner; Kerol Bartolovic; Sebastian Kreil; Ute Berger; Harald Gschaidmeier; Carsten Bokemeyer; Rüdiger Hehlmann; Klaus Dietz; Peter M Lansdorp; Lothar Kanz; Andreas Hochhaus
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.
Annals of the New York Academy of Sciences 2003;996():26-38.
2003: Stefan Fruehauf; Julian Topaly; Moritz Schad; Peter Paschka; Harald Gschaidmeier; W Jens Zeller; Andreas Hochhaus; Anthony Ho
Imatinib restores expression of CD62L in BCR-ABL-positive cells.
Journal of leukocyte biology 2003;73(5):600-3.
2003: Andreas Hochhaus
Cytogenetic and molecular mechanisms of resistance to imatinib.
Seminars in hematology 2003;40(2 Suppl 2):69-79.
2003: Ralf-Dieter Hofheinz; Andreas Weisser; Andreas Willer; Rüdiger Hehlmann; Andreas Hochhaus
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
Onkologie 2003;26(2):161-4.
2003: Barbara Wassmann; Urban J Scheuring; Christian Thiede; Heike Pfeifer; Martin Bornhäuser; F Griesinger; Andreas Hochhaus; Eberhard Schleyer; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Bone marrow transplantation 2003;31(7):611-4.
2003: Stephen G O'Brien; françois guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan Lanng Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Andrew Lamb; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
The New England journal of medicine 2003;348(11):994-1004.
2003: Andreas Reiter; Susanne Saussele; David Grimwade; Joseph L Wiemels; Mark Segal; Marina Lafage-Pochitaloff; Christoph Walz; Andreas Weisser; Andreas Hochhaus; Andreas Willer; Anja Reichert; Thomas Büchner; Eva Lengfelder; Rüdiger Hehlmann; Nicholas C P Cross
Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia.
Genes, chromosomes & cancer 2003;36(2):175-88.
2003: Tim H Brümmendorf; Inci Ersöz; Ulrike Hartmann; Kerol Bartolovic; Stefan Balabanov; Alexandra Wahl; Peter Paschka; Sebastian Kreil; Tanja Lahaye; Ute Berger; Harald Gschaidmeier; Carsten Bokemeyer; Rüdiger Hehlmann; Klaus Dietz; Peter M Lansdorp; Lothar Kanz; Andreas Hochhaus
Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.
Blood 2003;101(1):375-6.
2003: Andreas Burchert; Stefan Wölfl; Manuel Schmidt; Cornelia Brendel; Barbara Denecke; Dali Cai; Larissa Odyvanova; Tanja Lahaye; Martin C Müller; Thomas Berg; Harald Gschaidmeier; Burghardt Wittig; Rüdiger Hehlmann; Andreas Hochhaus; Andreas Neubauer
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
Blood 2003;101(1):259-64.
2002: Martin C Müller; Kirsten Merx; Andreas Weisser; Sebastian Kreil; Tanja Lahaye; Rüdiger Hehlmann; Andreas Hochhaus
Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization.
Leukemia 2002;16(12):2395-9.
2002: Ralf-Dieter Hofheinz; Gernot Hartung; Stephan Samel; Michael Emig; Lothar Pilz; Frank Willeke; Andreas Hochhaus; Rüdiger Hehlmann; Wolfgang Queisser
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Anti-cancer drugs 2002;13(10):999-1004.
2002: Andreas Hochhaus; Sebastian Kreil; Amie S Corbin; Paul La Rosée; Martin C Müller; Tanja Lahaye; B Hanfstein; Claudia Schoch; Nicholas C P Cross; Ute Berger; Harald Gschaidmeier; Brian J Druker; Rüdiger Hehlmann
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Leukemia 2002;16(11):2190-6.
2002: Martin C Müller; Tanja Lahaye; Andreas Hochhaus
[Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells].
Deutsche medizinische Wochenschrift (1946) 2002;127(42):2205-7.
2002: Andreas Hochhaus; Ute Berger; Andreas Reiter; Georg Engelich; Tanja Lahaye; Sebastian Kreil; Kirsten Merx; Martin C Müller; Rüdiger Hehlmann
[Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group].
Der Internist 2002;43(10):1228, 1231-8, 1241-4.
2002: Oliver G Ottmann; Brian J Druker; Charles L Sawyers; John M Goldman; Josy Reiffers; Richard T Silver; Sante Tura; Thomas Fischer; Michael W N Deininger; Charles Alan Schiffer; Michele Baccarani; Alois Gratwohl; Andreas Hochhaus; Dieter Hoelzer; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Stephen G O'Brien
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Blood 2002;100(6):1965-71.
2002: Kirsten Merx; Martin C Müller; Sebastian Kreil; Tanja Lahaye; Peter Paschka; Claudia Schoch; Andreas Weisser; C Kuhn; Ute Berger; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Leukemia 2002;16(9):1579-83.
2002: Thomas Fischer; C Reifenrath; G R Hess; Maria T Corsetti; Sebastian Kreil; J Beck; P Meinhardt; Germana Beltrami; B Schuch; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus; A Carella; Christoph Huber
Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT).
Leukemia 2002;16(7):1220-8.
2002: Ralf-Dieter Hofheinz; Gernot Hartung; Stephan Samel; Andreas Hochhaus; U Pichlmeier; Stefan Post; Rüdiger Hehlmann; Wolfgang Queisser
High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
Onkologie 2002;25(3):255-60.
2002: E Joanna Baxter; Andreas Hochhaus; Pascual Bolufer; Andreas Reiter; José M Fernandez; Leonor Senent; José Cervera; Federico Moscardo; Miguel A Sanz; Nicholas C P Cross
The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.
Human molecular genetics 2002;11(12):1391-7.
2002: Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; françois guilhot; Charles Alan Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood 2002;99(6):1928-37.
2002: Andreas Hochhaus
[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
Deutsche medizinische Wochenschrift (1946) 2002;127(9):451-6.
2002: Beate Schultheis; Melina Carapeti-Marootian; Andreas Hochhaus; Andreas Weisser; John M Goldman; Junia V Melo
Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism.
Blood 2002;99(5):1766-75.
2002: Andreas Hochhaus; Ute Berger; Andreas Reiter; Rüdiger Hehlmann
[Current pharmacotherapy of chronic myeloid leukemia].
Der Internist 2002;43(2):270-83.
2002: Andreas Hochhaus; Ute Berger; Andreas Reiter; Tanja Lahaye; Sebastian Kreil; Rüdiger Hehlmann
[Drug therapy of chronic myeloid leukemia].
Medizinische Klinik (Munich, Germany : 1983) 2002;97 Suppl 1():7-15.
2002: Andreas Hochhaus
Detection and quantification of leukemia-specific rearrangements.
Methods in molecular medicine 2002;68():67-96.
2001: J de la Fuente; Kirsten Merx; E J Steer; M Müller; R M Szydlo; Ole Maywald; Ute Berger; Rüdiger Hehlmann; J M Goldman; N C Cross; J V Melo; Andreas Hochhaus
ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia.
Blood 2001;98(9):2879-80.
2001: Andreas Hochhaus; Sebastian Kreil; Amie S Corbin; Paul La Rosée; Tanja Lahaye; Ute Berger; Nicholas C P Cross; W Linkesch; Brian J Druker; Rüdiger Hehlmann; C Gambacorti- Passerini; G Corneo; M D'Incalci
Roots of clinical resistance to STI-571 cancer therapy.
Science (New York, N.Y.) 2001;293(5538):2163.
2001: Andreas Hochhaus; Tanja Lahaye; Sebastian Kreil; Ute Berger; Georgia Metzgeroth; Rüdiger Hehlmann
[Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology].
Onkologie 2001;24 Suppl 5():65-71.
2001: Andreas Reiter; Andreas Hochhaus; Ute Berger; C Kuhn; Rüdiger Hehlmann
AraC-based pharmacotherapy of chronic myeloid leukaemia.
Expert opinion on pharmacotherapy 2001;2(7):1129-35.
2001: Manuel Schmidt; Andreas Hochhaus; Andreas Nitsche; Rüdiger Hehlmann; Andreas Neubauer
Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha.
Blood 2001;97(11):3648-50.
2000: Susanne Saussele; Andreas Weisser; Martin C Müller; M Emgi; Paul La Rosée; Peter Paschka; C Kuhn; Andreas Willer; Rüdiger Hehlmann; Andreas Hochhaus
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes.
Leukemia 2000;14(11):2006-10.
2000: Manuel Schmidt; Andreas Hochhaus; Sven A König-Merediz; Cornelia Brendel; J Proba; G J Hoppe; Burghardt Wittig; G Ehninger; Rüdiger Hehlmann; Andreas Neubauer
Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(19):3331-8.
2000: Eva Lengfelder; Anja Reichert; Claudia Schoch; Detlef Haase; Torsten Haferlach; Helmut Löffler; Peter Staib; Axel Heyll; Wolfgang Seifarth; Susanne Saussele; Christa Fonatsch; Winfried Gassmann; Wolf-Dieter Ludwig; Andreas Hochhaus; D Beelen; Carlo Aul; Maria Cristina Sauerland; Achim Heinecke; Rüdiger Hehlmann; Bernhard Wörmann; Wolfgang Hiddemann; Thomas Büchner
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Leukemia 2000;14(8):1362-70.
2000: Andreas Hochhaus; Andreas Weisser; Paul La Rosée; Michael Emig; Martin C Müller; Susanne Saussele; Andreas Reiter; C Kuhn; Ute Berger; Rüdiger Hehlmann; Nicholas C P Cross
Detection and quantification of residual disease in chronic myelogenous leukemia.
Leukemia 2000;14(6):998-1005.
2000: Andreas Hochhaus; Andreas Reiter; Susanne Saussele; Anja Reichert; Michael Emig; J Kaeda; Beate Schultheis; Ute Berger; P C Shepherd; N C Allan; Rüdiger Hehlmann; J M Goldman; Nicholas C P Cross
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
Blood 2000;95(1):62-6.
1999: Rüdiger Hehlmann; Andreas Hochhaus; Hans-Jochem Kolb; Joerg Hasford; Alois Gratwohl; Hermann Heimpel; Wolfgang Siegert; J Finke; Gerhard Ehninger; E Holler; Ute Berger; Markus Pfirrmann; A Muth; Axel Zander; A A Fauser; A Heyll; Christoph Nerl; Dieter K Hossfeld; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Andreas Tobler
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure.
Blood 1999;94(11):3668-77.
1999: Michael Emig; Susanne Saussele; H Wittor; Andreas Weisser; Andreas Reiter; Andreas Willer; Ute Berger; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Hochhaus
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.
Leukemia 1999;13(11):1825-32.
1999: A Krämer; S Hörner; A Willer; S Fruehauf; Andreas Hochhaus; M Hallek; Rüdiger Hehlmann
Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(5):2087-92.
1998: A Krämer; Andreas Hochhaus; Susanne Saussele; Anja Reichert; Andreas Willer; Rüdiger Hehlmann
Cyclin A1 is predominantly expressed in hematological malignancies with myeloid differentiation.
Leukemia 1998;12(6):893-8.
1998: Andreas Hochhaus; Ute Berger; A Krämer; Andreas Reiter; Wolfgang Seifarth; Andreas Willer; Rüdiger Hehlmann
Congress Report: XIX symposium of the International Association for Comparative Research on Leukemia and Related Diseases, Mannheim/Heidelberg, Germany, July 13 - 18, 1997.
European journal of medical research 1998;3(4):216-22.
1998: G Pasternak; Andreas Hochhaus; B Schultheis; Rüdiger Hehlmann
Chronic myelogenous leukemia: molecular and cellular aspects.
Journal of cancer research and clinical oncology 1998;124(12):643-60.
1998: Andreas Hochhaus; Ute Berger; A Krämer; Andreas Reiter; Wolfgang Seifarth; Andreas Willer; Rüdiger Hehlmann
XIX Symposium of the International Association for Comparative Research on Leukemia and Related Diseases, July 13-18 Mannheim/Heidelberg, Germany, 1997.
Journal of cancer research and clinical oncology 1998;124(3-4):220-30.
1998: Eva Lengfelder; Andreas Hochhaus; U Kronawitter; D Höche; Wolfgang Queisser; M Jahn-Eder; R Burkhardt; Andreas Reiter; H Ansari; Rüdiger Hehlmann
Should a platelet limit of 600 x 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages.
British journal of haematology 1998;100(1):15-23.
1998: Andreas Hochhaus; Andreas Reiter; H Skladny; Anja Reichert; Susanne Saussele; Rüdiger Hehlmann
Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1998;144():36-45.
1997: Andreas Hochhaus; F Lin; Andreas Reiter; H Skladny; Rüdiger Hehlmann; J M Goldman; N C Cross
Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction.
Leukemia 1997;11 Suppl 3():541-4.
1997: Rüdiger Hehlmann; Andreas Willer; Hermann Heimpel; Joerg Hasford; Hans-Jochem Kolb; Hans Pralle; Dieter K Hossfeld; Wolfgang Queisser; Helmut Löffler; Andreas Hochhaus; Andreas Tobler; Eva Lengfelder; Ute Berger; Christine Leib-Mösch
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group.
Leukemia 1997;11 Suppl 3():506-11.
1997: Andreas Reiter; Heyko Skladny; Andreas Hochhaus; Wolfgang Seifarth; H Heimpel; C R Bartram; N C Cross; Rüdiger Hehlmann
Molecular response of CML patients treated with interferon-alpha monitored by quantitative Southern blot analysis. German chronic myeloid leukaemia (CML) Study Group.
British journal of haematology 1997;97(1):86-93.
1997: Rüdiger Hehlmann; H Ansari; Joerg Hasford; Hermann Heimpel; Dieter K Hossfeld; Hans-Jochem Kolb; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Andreas Reiter; Andreas Hochhaus
Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group.
British journal of haematology 1997;97(1):76-85.
1996: Andreas Hochhaus; Rüdiger Hehlmann
[Chronic myeloid leukemia. Current strategies in diagnosis, therapy and follow-up].
Der Internist 1996;37(10):1013-21.
1996: Ricardo Aguiar; Heinz Sill; Andreas Hochhaus; John M Goldman; Nicholas C P Cross
Molecular investigation of secondary chronic myeloid leukemia.
Blood 1996;88(7):2808-9.
1996: Andreas Hochhaus; A Reiter; Heyko Skladny; Junia V Melo; C Sick; Ute Berger; J Q Guo; R B Arlinghaus; Rüdiger Hehlmann; John M Goldman; Nicholas C P Cross
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.
Blood 1996;88(6):2236-40.
1996: F Al-Jehani; Andreas Hochhaus; A Spencer; John M Goldman; Junia V Melo
Expression of the LH2 gene in chronic myeloid leukaemia cells.
Leukemia 1996;10(7):1122-6.
1996: F van Rhee; Andreas Hochhaus; F Lin; Junia V Melo; John M Goldman; Nicholas C P Cross
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
Blood 1996;87(12):5213-7.
1996: Andreas Hochhaus; F Lin; A Reiter; Heyko Skladny; Rüdiger Hehlmann; John M Goldman; Nicholas C P Cross
Quantitative molecular methods to monitor the response of CML patients to interferon-alpha.
Bone marrow transplantation 1996;17 Suppl 3():S41-4.
1996: Rüdiger Hehlmann; Hermann Heimpel; Dieter K Hossfeld; Joerg Hasford; Hans-Jochem Kolb; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Andreas Hochhaus; A Tichelli; W Fett; Norbert Schmitz; A Reiter; Martin Griesshammer; W Pfeifer; M Bümler; T Kamp; Andreas Tobler; Hartmut Eimermacher; R Kuse; Ute Berger; H Ansari
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.
Bone marrow transplantation 1996;17 Suppl 3():S21-4.
1996: Junia V Melo; Andreas Hochhaus; X H Yan; John M Goldman
Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia.
British journal of haematology 1996;92(3):684-6.
1996: Heinz Sill; Ricardo Aguiar; H Schmidt; Andreas Hochhaus; John M Goldman; Nicholas C P Cross
Mutational analysis of the p15 and p16 genes in acute leukaemias.
British journal of haematology 1996;92(3):681-3.
1996: Andreas Hochhaus; F Lin; A Reiter; Heyko Skladny; Philip J Mason; F van Rhee; P C Shepherd; N C Allan; Rüdiger Hehlmann; John M Goldman; Nicholas C P Cross
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.
Blood 1996;87(4):1549-55.
1995: Andreas Hochhaus; F Lin; A Reiter; Heyko Skladny; F van Rhee; P C Shepherd; N C Allan; Rüdiger Hehlmann; John M Goldman; Nicholas C P Cross
Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.
British journal of haematology 1995;91(1):126-31.
1995: F van Rhee; D I Marks; F Lin; Richard Szydlo; Andreas Hochhaus; J Treleaven; C Delord; Nicholas C P Cross; John M Goldman
Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow.
Leukemia 1995;9(2):329-35.
1994: Rüdiger Hehlmann; Hermann Heimpel; Joerg Hasford; Hans-Jochem Kolb; Hans Pralle; Dieter K Hossfeld; Wolfgang Queisser; Helmut Löffler; Andreas Hochhaus; Barbara Heinze
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
Blood 1994;84(12):4064-77.
1994: Rüdiger Hehlmann; H Ansari; V Adelberger; Barbara Heinze; K Hossfeld; Andreas Hochhaus; Hermann Heimpel
New perspectives with interferon alpha. The German CML study group experience.
Bone marrow transplantation 1994;14 Suppl 3():S14-20.
1993: Martin Griesshammer; Rüdiger Hehlmann; Andreas Hochhaus; Moshe Talpaz; S Tura; P Stryckmans; N C Allan; J Tanzer; H J Kolb; Hermann Heimpel
Interferon in chronic myeloid leukemia. A workshop report.
Annals of hematology 1993;67(2):101-6.
1993: Rüdiger Hehlmann; Hermann Heimpel; Hans-Jochem Kolb; Barbara Heinze; Andreas Hochhaus; Martin Griesshammer; Hans Pralle; Wolfgang Queisser; U Essers; C Falge
The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
Leukemia & lymphoma 1993;11 Suppl 1():159-68.
1991: Rüdiger Hehlmann; H Heimpel; Barbara Heinze; A Georgii; Hans-Jochem Kolb; Dieter K Hossfeld; P von Wussow; Andreas Hochhaus; Martin Griesshammer; V Diehl
[Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)].
Onkologie 1991;14(1):66-73.
1990: Andreas Hochhaus; K Mindner; G Ostermann; D Höche
[Aggregative behavior and calcium content of platelets in thrombocythemia and thrombocytosis].
Folia haematologica (Leipzig, Germany : 1928) 1990;117(6):765-70.
1989: Andreas Hochhaus; D Höche; K Mindner; G Ostermann; M Meyer
[Megakaryocytic myelosis--clinical aspects, morphology and platelet function].
Klinische Wochenschrift 1989;67(2):51-9.
1988: Andreas Hochhaus; K Wutke; M Meyer
[Hereditary elliptocytosis with detection of a membrane protein defect of erythrocytes].
Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete 1988;43(5):128-9.
1988: K Mindner; G Ostermann; Andreas Hochhaus; D Höche; U Till
Blood platelet calcium content and aggregation behaviour in myeloproliferative disorders and secondary thrombocytosis.
Folia haematologica (Leipzig, Germany : 1928) 1988;115(4):461-4.